Dr. Helen Torley, President and CEO of Halozyme, stated that the company’s analysis of the Centers for Medicare & Medicaid Services (CMS) proposal, alongside the statutory framework of the One Big Beautiful Bill Act, suggests no threat to its financial trajectory. Beyond royalty stability, the firm expects no disruption to its ability to secure new partnership agreements for its ENHANZE drug delivery technology.
In section Releases
Halozyme Projects Minimal Medicare Royalty Impact Through 2035
San Diego-based Halozyme Therapeutics confirmed it expects zero to minimal impact on its royalty revenues through at least 2035 following an internal review of the latest draft Medicare Drug Price Negotiation Program rules. The company maintains that its core business model remains insulated from the proposed federal regulatory changes.
The company’s outlook relies on specific provisions within the CMS draft that preserve protections for orphan drugs and account for the market entry of biosimilars. Halozyme intends to maintain a dialogue with federal regulators to advocate for policies that prioritize therapeutic innovation. The biopharmaceutical firm continues to license its proprietary enzyme technology to major global partners, including Roche, Takeda, and Pfizer, to facilitate subcutaneous drug delivery.
Comments (0)
No comments yet. Be the first!